Date: 2018-07-03
Type of information: Licensing agreement
Compound: bi-valent ganglioside based vaccine
Company: Y-mAbs Therapeutics (USA - NY) MabVax Therapeutics (USA - CA)
Therapeutic area: Cancer - Oncology - Rare diseases
Type agreement: licensing
Action mechanism:
- immunotherapy product/therapeutic vaccine. MV-NB-02 is a bivalent vaccine that elicits an antibody response targeting the two most common antigens on neuroblastoma cells with the objective of killing residual cancer cells that can cause recurrence.
Disease: neuroblastoma
Details:
- • On July 3, 2018, MabVax Therapeutics has granted to Y-mAbs Therapeutics an exclusive sublicense to a bi-valent ganglioside based vaccine intended to treat neuroblastoma, a rare pediatric cancer. The neuroblastoma vaccine was originally developed by Dr. Philip Livingston and colleagues at Memorial Sloan Kettering Cancer Center (MSK) and licensed as part of a broader portfolio of anti-cancer vaccines to MabVax. MabVax filed for and was granted an Orphan Drug Designation for the neuroblastoma vaccine and has manufactured Phase II clinical supplies for a planned but not initiated clinical trial to be conducted with the consortium New Advances in Neuroblastoma Therapy (NANT). NANT is the only consortium of academic medical centers in the world solely dedicated to developing novel treatments and biomarkers for children with Neuroblastoma. Over the last several years MabVax has shifted its focus and resources to its human antibody discovery and development programs that are currently in early stage clinical trials and have attracted partner interest.
- A third of neuroblastoma patients are diagnosed as infants; and ninety percent are younger than five years of age at time of diagnosis. Neuroblastoma is responsible for twelve percent of all cancer deaths in children less than 15 years of age.
Financial terms:
- Total value of the transaction to MabVax is $1.3 million plus a share of a Pediatric Disease Voucher if granted by the FDA to Y-mAbs on approval of the vaccine and the Pediatric Disease Voucher is subsequently sold. Additionally, Y-mAbs will be responsible for all further development of the product as well as any downstream payment obligations related to this specific vaccine to MSK that were specified in the original MabVax-MSK license agreement. If Y-mAbs successfully develops and receives FDA approval for the Neuroblastoma vaccine, it is obligated to file with the FDA for a Pediatric Disease Voucher. If the voucher is granted to Y-mAbs and subsequently sold, then MabVax will receive a percentage of the proceeds from the sale of the voucher by Y-mAbs.
Latest news:
Is general: Yes
